Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus infection in ferrets.

Pearce MB, Belser JA, Gustin KM, Pappas C, Houser KV, Sun X, Maines TR, Pantin-Jackwood MJ, Katz JM, Tumpey TM.

J Virol. 2012 Jul;86(13):7118-25. doi: 10.1128/JVI.00674-12. Epub 2012 May 2.

2.

Immunization with live virus vaccine protects highly susceptible DBA/2J mice from lethal influenza A H1N1 infection.

Dengler L, May M, Wilk E, Bahgat MM, Schughart K.

Virol J. 2012 Sep 19;9:212. doi: 10.1186/1743-422X-9-212.

3.

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.

J Virol. 2005 Mar;79(5):2910-9.

4.

Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design.

Ichinohe T.

Expert Rev Vaccines. 2010 Nov;9(11):1315-24. doi: 10.1586/erv.10.118. Review.

PMID:
21087109
6.
7.
8.

The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection.

Lau YF, Wright AR, Subbarao K.

J Virol. 2012 May;86(9):5089-98. doi: 10.1128/JVI.07205-11. Epub 2012 Feb 29.

9.

A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks.

Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H.

J Virol. 2011 Nov;85(21):10989-98. doi: 10.1128/JVI.05420-11. Epub 2011 Aug 24.

11.

Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets.

Chen GL, Min JY, Lamirande EW, Santos C, Jin H, Kemble G, Subbarao K.

J Infect Dis. 2011 Apr 1;203(7):930-6. doi: 10.1093/infdis/jiq144. Epub 2011 Jan 21.

12.

Efficacy of single dose of a bivalent vaccine containing inactivated Newcastle disease virus and reassortant highly pathogenic avian influenza H5N1 virus against lethal HPAI and NDV infection in chickens.

Lee DH, Park JK, Kwon JH, Yuk SS, Erdene-Ochir TO, Jang YH, Seong BL, Lee JB, Park SY, Choi IS, Song CS.

PLoS One. 2013;8(3):e58186. doi: 10.1371/journal.pone.0058186. Epub 2013 Mar 1.

13.

A DNA vaccine expressing PB1 protein of influenza A virus protects mice against virus infection.

Košík I, Krejnusová I, Práznovská M, Poláková K, Russ G.

Arch Virol. 2012 May;157(5):811-7. doi: 10.1007/s00705-012-1238-6.

PMID:
22294447
14.

Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.

Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T.

Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10.

PMID:
21911027
15.

Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.

Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, Takahashi M, Yamanishi K, Mori Y.

Vaccine. 2009 Sep 25;27(42):5896-905. doi: 10.1016/j.vaccine.2009.07.037. Epub 2009 Jul 31.

PMID:
19647814
16.

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T, Hasegawa H.

J Infect Dis. 2007 Nov 1;196(9):1313-20. Epub 2007 Oct 5.

PMID:
17922395
17.

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Fang F, Zheng M, Chen Z.

Vaccine. 2010 Nov 10;28(48):7690-8. doi: 10.1016/j.vaccine.2010.09.019. Epub 2010 Sep 24.

PMID:
20870054
18.

No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009.

Mahmud SM, Van Caeseele P, Hammond G, Kurbis C, Hilderman T, Elliott L.

Emerg Infect Dis. 2012 May;18(5):801-10. doi: 10.3201/eid1805.111596.

19.

Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.

Okamoto S, Yoshii H, Akagi T, Akashi M, Ishikawa T, Okuno Y, Takahashi M, Yamanishi K, Mori Y.

Vaccine. 2007 Nov 28;25(49):8270-8. Epub 2007 Oct 11.

PMID:
17977633
20.

Supplemental Content

Support Center